Autumn Research Update Meeting 2025
Our 2025 Autumn Research Update Meeting will take place once again at the renowned Royal Society of Medicine (RSM), Wimpole Street, London, on Monday 10 November, where guests can look forward to an engaging agenda featuring the latest updates from our funded research. Theme: Revolutionising...
Learn more
DROPS UCI vs. Tindall & Co: Chase! In aid of Cure Parkinson’s
On 16 January, over 800 riders from across the globe took to their turbo trainer bikes at home and joined the epic DROPS UCI vs. Tindall & Co: Chase, a virtual cycling event on Zwift, raising vital funds and awareness of our research. This unique…
Webinar – Coronavirus and Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. This webinar discusses recent publications about Coronavirus and Parkinson’s. The eminent panel, once again chaired by Professor Patrik Brundin (Van Andel Institute) comprises Dr Alberto Fasano (University of Toronto), Dr David Beckham…
The need for novel c-Abl inhibitors
A protein called Abelson Tyrosine Kinase – or c-Abl – is believed to be involved in the biological processes leading to loss of dopamine neurons in the brains of people with Parkinson’s. In many preclinical studies, stopping the harmful c-Abl processes with the use of drugs called c-Abl inhibitors have found that c-Abl activity decreases….
The AIM-PD trial (ambroxol)
Supported and funded by Cure Parkinson’s, Van Andel Institute and the John Black Foundation, the next phase of this trial programme will follow shortly. Phase 2 of the ‘AIM-PD’ study was a proof of concept study and involved 17 people with the genetic form of Parkinson’s over…
The UP-Study trial (UDCA)
This trial is now complete. Supported by Cure Parkinson’s and the J P Moulton Foundation, the results are expected in 2021. Originally used to treat cirrhosis of the liver, researchers found that the rescue effect of UDCA on the liver cells may actually be due…